Content Type: Article

  • SB 5387 Seeks to Implement Restrictive Corporate Practice of Healthcare Prohibition in Washington

    SB 5387 Seeks to Implement Restrictive Corporate Practice of Healthcare Prohibition in Washington

    ARTICLE / CLIENT ALERT

    SB 5387 Seeks to Implement Restrictive Corporate Practice of Healthcare Prohibition in Washington

    February 28, 2025

    Read time: 7 min

    Key takeaways
    Overview

    On January 21, 2025, the Washington state legislature introduced Senate Bill (SB) 5387, aiming to codify a restrictive state prohibition on the corporate practice of healthcare, commonly referred to as a corporate practice of medicine (CPOM) doctrine. If enacted, the bill would prohibit any nonlicensed entities from owning a medical practice, employing licensed healthcare providers, or otherwise engaging in the practice of a healthcare profession, subject to limited exceptions. Such restrictions would become effective January 1, 2027. The bill is scheduled for public hearing in the Senate Ways & Means Committee on February 26, 2025.

    In depth

    Background

    Washington state does not currently maintain an explicit CPOM statute, relying instead on court and agency interpretations of its prohibition on the practice of medicine by unlicensed persons to include business entities. The current interpretation of the doctrine has enabled Washington stakeholders to operate healthcare entities under industry standard models, including the “affiliated practice” model (e.g., physician practice management structures with stock transfer restriction agreements). SB 5387 seeks to codify and expand upon agency interpretations in a manner that would prohibit certain critical elements of these models.

    SB 5387 Provisions

    Prohibitions on Ownership

    If enacted, SB 5387 would prohibit unlicensed individuals or entities, including corporations and partnerships, from:

    • Owning a healthcare practice
    • Employing licensed healthcare providers
    • Otherwise engaging in a licensed healthcare profession, unless specifically permitted under state laws.

    For professional service corporations organized for the purpose of establishing a healthcare practice, SB 5387 would institute certain ownership and governance requirements. Specifically, licensed healthcare providers would be required to:

    • Hold the majority of each class of shares entitled to vote
    • Represent a majority of the directors
    • Hold all officer positions other than the secretary and treasurer.

    If enacted, SB 5387 would institute an active practice requirement, under which shareholders who are healthcare providers licensed in Washington must be substantially engaged in delivering care or managing the practice. In prior iterations of the bill, SB 5387 included a requirement for shareholders to be physically present in Washington. Such in-state presence requirement would significantly curtail the ability of operators of multistate telehealth offerings to function in Washington state.

    Prohibitions on Certain Arrangements by Shareholders, Directors, and Officers

    SB 5387 aims to prohibit certain actions and financial arrangements by the shareholders, directors, and officers of a healthcare practice through prohibitions of “dual ownership” and “dual employment.” While these structures have been used in the past to promote financial alignment between physicians and investors in affiliated practice models, critics have posited that the dual nature of such offerings might indirectly impact a clinician’s independent professional judgment. SB 5387 would prohibit shareholders, directors, and officers from:

    • Owning or controlling shares in a management services organization (MSO) with which the healthcare practice has a contract (contracted MSO)
    • Serving as a director or officer of a contracted MSO
    • Being an employee of or an independent contractor with a contracted MSO
    • Otherwise participating in managing both the healthcare practice and a contracted MSO
    • Receiving substantial compensation or remuneration from an MSO in return for ownership or management of the healthcare practice
    • Transferring or relinquishing control over the sale, the restriction of the sale, or the encumbrance of the sale of the healthcare practice’s shares or assets
    • Transferring or relinquishing control over the issuing of shares of stock in the healthcare practice, a subsidiary of the healthcare practice, or an entity affiliated with the healthcare practice, or over the paying of dividends
    • Entering into any financial arrangement in violation of the rebating prohibition.

    Shareholders who are licensed healthcare providers of the health practice (licensed shareholders) also would be prohibited from transferring or relinquishing control over any of the healthcare practice’s administrative, business, or clinical operations that may affect clinical decision-making or the nature or quality of care that the healthcare practice delivers, whether:

    • By means of a contract or other agreement or arrangement
    • By providing for such control in the healthcare practice’s articles of incorporation or bylaws
    • By forming a subsidiary or affiliated entity
    • By other means.

    SB 5387 clarifies that a licensed shareholder may still consult or collaborate with other persons on the development of policies or decisions that affect clinical decision-making or the nature or quality of care, as long as the licensed shareholder makes the ultimate decision.

    Prohibited Activities by Various Other Entities

    The prohibitions discussed above would not apply to:

    • Hospitals licensed in Washington or any other state
    • Any entity controlled by a hospital licensed in Washington or any other state
    • Private establishments (as defined under Washington law)
    • Nursing homes
    • Ambulatory surgical facilities
    • Birthing centers
    • In-home service agencies
    • Federally qualified health centers
    • Telemedicine-exclusive medical groups.

    Instead, SB 5387 addresses such entities separately. The bill includes certain limitations on the actions of unlicensed persons employed by, contracted with, or affiliated with these entities. If passed, SB 5387 would prohibit unlicensed persons from interfering with, controlling, or otherwise directing the professional judgment or clinical decisions of a licensed healthcare provider providing care within their scope of practice to a patient at the facility.

    This proposed prohibition includes, but is not limited to, use of policy, discipline, punishment, threats, adverse employment actions, coercion, retaliation, or excessive pressure to control any of the following:

    • The period of time a provider may spend with a patient
    • The period of time within which a healthcare provider must discharge a patient
    • The clinical status of the patient, including decisions on admission, observation status, care and referrals
    • The diagnoses, diagnostic terminology, or codes that are entered into the medical record by the healthcare provider
    • The range of clinical orders available to a healthcare provider.

    This prohibition would not preclude any policies requiring that a healthcare provider comply with laws. If passed, SB 5387 would permit healthcare provider policies regarding compliance with coding guidelines, third-party payor requirements, and credentialing guidelines. Further, SB 5387 would permit healthcare provider policies regarding privilege requirements, quality improvement standards, peer review, quality incentive programs, co-management arrangements, or value-based care initiatives.

    Enforcement

    SB 5387 would empower the Washington state secretary of health to investigate complaints, hold hearings, and issue subpoenas in connection with violations of the CPOM prohibitions. The secretary may further issue cease-and-desist letters and impose financial penalties.

    Upon application for a license or license renewal, a healthcare provider would be required to attest, in a form and manner determined by the Washington medical commission, that the healthcare provider is aware of Washington’s CPOM prohibitions.

    Key Definitions

    • “Management services organization” means any organization or entity that contracts with a professional service corporation to perform management or administrative services relating to, supporting, or facilitating the provision of healthcare services.
    • “Telemedicine-exclusive medical group” means an entity that engages with patients exclusively through telemedicine and does not offer in-person healthcare services.
    • “Telemedicine” means the delivery of healthcare services through the use of interactive audio and video technology, permitting real-time communication between the patient at the originating site and the provider, for the purpose of diagnosis, consultation, or treatment. “Telemedicine” includes audio-only telemedicine but does not include facsimile or email.

    Analysis

    The CPOM prohibition has been active in Washington for decades.   SB 5387 seeks to implement a far more restrictive CPOM prohibition than is currently in place. If passed, SB 5387 would significantly restrict current and future transaction structures that utilize certain financial arrangements, such as equity transfer restriction agreements, common to the industry and considered necessary for lay investment in healthcare entities.

    McDermott will continue to monitor the bill’s progression through the state legislature and provide updates.

    Key Takeaways

    If SB 5387 is passed:

    • The CPOM doctrine will be codified and significantly expanded such that unlicensed persons and entities would not be able to own a healthcare practice, employ licensed healthcare providers, or otherwise engage in a licensed healthcare profession.
    • Shareholders, directors, and officers of professional healthcare entities would be prohibited from owning shares; being a director, officer, employee, or independent contractor of; or participating in the management of an MSO under contract with the healthcare practice, except under limited circumstances.
    • Equity transfer restriction agreements between professional healthcare entities and MSOs would be significantly limited.
    Authors

    Patrick Zanayed

    Partner

    Chicago

    Larry C. Guess

    Partner

    Chicago

    Jae Hyun Lee

    Associate

    New York – One Vanderbilt Avenue

    More insights

  • Data Privacy and Cybersecurity in 2025: EU Data Act and Cybersecurity Frameworks

    Data Privacy and Cybersecurity in 2025: EU Data Act and Cybersecurity Frameworks

    ARTICLE

    Data Privacy and Cybersecurity in 2025: EU Data Act and Cybersecurity Frameworks

    February 28, 2025

    Read time: 7 min

    Key takeaways
    Overview

    Following our client alert at the beginning of the year, learn more about the EU data and cybersecurity regulations and their impact on organizations in 2025. Rosa Barcelo, Romain Perray, Julie Favreau, and Matúš Huba share additional insights from working with clients on these issues.

    In depth

    What makes the EU Data Act more difficult to implement than the other EU Digital Package regulations, and how should companies prepare for compliance?

    The Data Act is particularly challenging for companies to implement due to its complex scope of application.

    First, the regulation is divided into several chapters, and their interplay is not always clear. Certain chapters appear to be autonomous and apply to different categories of stakeholders. A company could therefore fall within the scope of a specific chapter of the Data Act (e.g., Chapter VI “Switching between data processing services”) without being affected by the others. Similarly, it is arduous for companies to determine which category of stakeholders they belong to, as certain definitions vary from one chapter to another. For instance, the term “data holder” refers to both natural and legal persons under any chapter of the text, except for Chapter V, which applies only to legal persons.

    Additionally, more so than other EU Digital Package regulations, the Data Act must interlock with various other texts, especially the General Data Protection Regulation and the ePrivacy Directive. This means that companies covered by chapters relating to connected devices and related services (i.e., Chapters II and III) must identify whether some of the data generated by the device could qualify as “personal data.” To do so, companies are expected to create a data library based on a triage mechanism and monitor the evolution of the data lifecycle of the connected product or related service to keep the library updated.

    Finally, the Data Act provides different timelines for different obligations and according to various criteria. This is another challenging area for companies subject to the law.

    As a first step towards Data Act compliance, companies should perform an in-depth audit of their activities based on the abovementioned topics to determine if they fall within the scope of application of the text and, if so, on what grounds.

    What are the main challenges you see clients encounter in implementing the EU Data Act, and how do you help overcome them?

    Our clients generally struggle with:

    1. Listing the exact data their connected device and/or related service generate.
    2. Classifying such data, particularly identifying whether some of it falls within the exemptions provided by the Data Act (e.g., inferred or derived data and content data).
    3. The technical means to make the data available, including triage between non-personal data and personal data.
    4. The possibility of invoking trade secrets to deny access to data.
    5. The different timelines which may overlap depending on the concerned obligation.
    6. The scope of the “provider of data processing service” which can be defined as a natural or legal person who provides data processing services (i.e., not the one who relies on the services provided by another).

    To help clients overcome the abovementioned issues, we suggest the following action plan:

    1. Providing training sessions to ensure that relevant teams are entitled to cope with the various obligations stemming from the Data Act.
    2. Conducting an analysis of the company’s activity to determine whether it falls within the scope of the Data Act and on what grounds.
    3. If relevant, performing a high-level audit of the existing data flows and channel mechanisms.
    4. If relevant, designing the data library from a legal perspective and assessing the most appropriate triage mechanism in case of personal data access.
    5. Drafting appropriate internal procedures and transparency notices.
    6. Analyzing existing cloud services contracts and adjusting them accordingly.

    How does compliance differ across the three EU cybersecurity frameworks (the Network and Information Security 2 (NIS2) Directive, the Digital Operational Resilience Act (DORA), and the Cyber Resilience Act)?

    All three frameworks have the same functionality, which is to improve cybersecurity posture in different digital areas. While NIS2 provides baseline requirements for networks and information systems of essential and important businesses active in a broad range of sectors (from energy to health and digital infrastructure, among others), DORA focuses on financial entities and their service providers. The Cyber Resilience Act applies to a wide range of products with digital elements (both software and hardware).

    Entities that comply with DORA are exempt from the equivalent NIS2 requirements on cybersecurity risk-management measures and incident notification (and related enforcement and supervision). The Cyber Resilience Act complements NIS2 and is not intended to overlap. Similarly to the DORA-NIS2 relationship, compliance with relevant sectoral legislation may (partially) exclude application of the Cyber Resilience Act.

    Member States will decide the level of fines applicable to each framework. NIS2 sets a minimal highest fine level (at least EUR 7 million/10 million or 1.4%/2% of the total worldwide annual turnover in the preceding financial year of the group, whichever is higher, depending on whether entity is important or essential). The Cyber Resilience Act sets maximum fines levels as well (up to EUR 15 million or up to 2.5% of the total worldwide annual turnover in the preceding financial year of the group, whichever is higher, in case of the most serious breaches, with lower thresholds applicable to less serious violations).

    Both NIS2 and DORA allow for personal liability of management bodies (and other responsible individuals) for infringements under both frameworks. Such liability may take the form of civil, criminal, or administrative penalties, depending on local law.

    What are the common questions your clients have about the EU cybersecurity frameworks, and how do you address them?

    Client inquiries are mostly focused on NIS2 and DORA. This makes sense because both statutes are fully applicable, whereas the Cyber Resilience Act will only apply from the end of 2026.

    One of the preliminary NIS2 questions many clients ask is, “Does NIS2 apply to me?” This is because, compared to its predecessor, the scope of application of NIS2 is much broader and encompasses more businesses. Some clients are surprised to discover that they are now fully covered by it. For example, the manufacturing sector is now covered and includes many types of devices, from electric equipment to machinery, motor vehicles, trailers, and many others.

    Companies that must comply with NIS2 often ask for help to bring themselves into compliance. For example, NIS2 imposes an obligation for covered entities to register with local regulators, and we have supported clients in preparing such registrations. We have also assisted clients in preparing cybersecurity training for boards of directors, which is mandatory. Another area where companies need support is in relation to cybersecurity controls and reporting incidents. NIS2 has triggered the need to create or update standard operating procedures to manage and notify cybersecurity incidents. Finally, jurisdictional issues are a common challenge for many clients. A recurrent query is to help companies understand which of the 27 Member States have jurisdiction over the company and/or its affiliates, including whether NIS2 also applies to entities not established in the EU but offering services in the EU.

    Questions regarding the application of DORA come from financial entities as well as service providers of financial entities within the scope of DORA. Depending on whether such service providers are essential or third-party providers, the service agreements with the financial entities must contain certain contractual safeguards, such as provisions on availability, authenticity, integrity, and confidentiality in relation to the protection of data.  We often help providers determine their status (essential versus third-party provider) and prepare or negotiate DORA amendments to service contracts.

    Authors
    More insights

  • Quarterly Sanctions Update | Q4 2024 / Q1 2025

    Quarterly Sanctions Update | Q4 2024 / Q1 2025

    ARTICLE / CLIENT ALERT

    Quarterly Sanctions Update | Q4 2024 / Q1 2025

    February 28, 2025

    Read time: 11 min

    Key takeaways
    Overview

    What’s New? The European Union and the United Kingdom remain committed “to keep up the pressure on the Kremlin” by way of imposing further sanctions as Russia’s illegal invasion of Ukraine enters the fourth year. Within a course of the last three months, the EU adopted two new sanctions packages, with new restrictions ranging from asset freezes imposed on over a hundred of individuals, companies and vessels to banning imports of aluminum originating in Russia. The United Kingdom followed the European Union’s suit, imposing new sanctions as recently as February 24, 2025.

    US Policy Changes. Stay ahead of US law and policy changes, including shifting restrictive trade measures under the current administration, with our dedicated US Policy Watch resource center.

    Clarifying the Rules. The European Commission issued a series of long-awaited clarifications on the ‘best efforts’ and ‘no re-export to Russia’ clause requirements. The UK Office of Trade Sanctions Implementation (OTSI) also provided new guidance on ‘no Russia’ clauses, highlighting their role in due diligence best practices.

    Expanding Sanctions Reporting. In the United Kingdom, a new group of companies, including insolvency practitioners, letting agents and art market participants, now fall under the reporting requirements relating to Russia sanctions.

    Easing Pressure on Syria. The EU agreed to suspend certain sanctions against Syria following the collapse of President Assad’s regime in December 2024. The United Kingdom has announced its willingness to implement similar measures on February 13, 2025.

    In depth

    European Union

    The European Union adopted its 16th sanctions package against Russia on February 24, 2025, barely two months after adopting the 15th sanctions package. Both packages reinforce anti-circumvention measures as well as expand the lists of sanctioned individuals, entities and vessels. Moreover, the deadline for applying for licenses authorizing prohibited activities in the context of divestment from Russia has been extended until December 31, 2025. EU sanctions against Belarus have been updated accordingly.

    Whilst the focus remains on weakening Russia’s energy revenues by listing nearly 150 vessels and further targeting actors associated with trade in crude oil or petroleum products, the European Union did not reach an agreement on prohibiting the import of liquefied natural gas (LNG) from Russia.

    Below are some key new restrictions introduced by the 16th sanctions package which, with a few exceptions, apply from February 25, 2025:

    • Foreign entities and individuals: The European Union continues to exert extraterritoriality by listing 34 new companies established in countries other than Russia which are suspected of supporting Russia’s military-industrial complex or are otherwise engaged in sanctions circumvention. This builds on from the 15th sanctions package which listed two senior officials from North Korea as well as the ‘fully-fledged listings’ (i.e. a travel ban, an asset freeze and a prohibition to make funds available) on seven Chinese persons and entities facilitating the circumvention of EU sanctions, supplying sensitive drone and microelectronic components to the Russian military industry.
    • Russian banks and financial institutions: Engaging in transactions with the following banks is now prohibited: BelVEB, Belgazprombank, and VTB Bank (PJSC) Shanghai Branch. As of March 17, 2025, providing specialised financial messaging services to the following Russian banks and financial institutions will also be prohibited: Ak Bars Bank, Uralsib Bank, Tochka Bank, National Reserve Bank, Roseximbank, Bank Sinara, Primsotsbank, BBR Bank, RNKO Platezhnyy Konstruktor, Petersburg’s settlement center, Kuznets business Bank, MIR Business Bank, and Bank Kuban Kredit.
    • Media outlets: Broadcasting, including through satellite and internet video-sharing platforms or applications, any content provided by the following Russian media outlets is no longer authorised: EADaily / Eurasia Daily, Fondsk, Lenta, NewsFront, RuBaltic, SouthFront, Strategic Culture Foundation, and Krasnaya Zvezda / Tvzvezda.
    • Import restrictions: Importing primary aluminum from Russia into the European Union is now prohibited. This builds on the existing prohibition relating to the import of processed aluminum goods from Russia. However, to ensure a smooth transition for EU businesses, a quota mechanism has been introduced over a 12-month period.
    • Export restrictions: The list of restricted goods now includes additional minerals, chemicals, steel, glass materials and fireworks, as well as software related to machine tools used to manufacture weapons and video-game controllers. The export of these goods to Russia is prohibited.
    • Transport: Engaging in transactions with certain Russian airports, including Vnukovo Airport, Zhukovsky Airport, and four regional airports, as well as certain Russian ports, including Volga, Astrakhan, Makhachkala, Ust-Luga, Primorsk, and Novorossiysk, is now prohibited.
    • Services: Providing construction services to the Russian Government or entities established in Russia is no longer permitted. While no exemptions are available for pre-existing contracts, EU companies may apply to the relevant authorities for a license authorizing any such activities.
    • Crypto: Garantex, a Russian crypto-currency exchange is now subject to EU asset-freeze restrictions and any engagement with Garantex is prohibited. In a first, EU sanctions have listed the known blockchain wallet address of the sanctioned entity.
    • New guidance: The European Commission amended its Frequently Asked Questions on Russia sanctions (FAQ) with long-awaited clarifications. Specifically:
      • Best efforts: On November 22, 2024, the European Commission clarified that the determination on whether a business has actually exercised its ‘best efforts’ under Article 8a of EU Regulation 833/2014 will depend on the nature, size and risk profile of the business itself. The Commission holds that ‘best efforts’ may include: the implementation of internal compliance programs, systematic sharing of corporate compliance standards, sending internal newsletters and sanctions advisories, organizing mandatory reporting on sanctions breaches, and/or organising mandatory sanctions trainings.

        According to the FAQ, any of the following activities may amount to a breach of the ‘best efforts’ obligation: knowledge of activities undermining EU sanctions, failure to block transactions undermining EU sanctions and/or failure to carry out appropriate due diligence regarding activities of non-EU subsidiaries which resulted in undermining EU sanctions. Explore more on the impact of this FAQ on EU investment funds and corporates.

      • Circumvention and due diligence. On December 11, 2024, the European Commission reiterated that due diligence must be conducted on multiple levels, including at stakeholders’ level, transaction level including flows of money, as well as the transportation of goods level. Furthermore, EU operators should remember to identify any threats and vulnerabilities in their sanctions compliance processes, conduct an appropriate risk analysis and regularly update their policies.
      • Enhanced due diligence for manufacturers of common high priority items. On December 11, 2024, the European Commission clarified that the sanctions policies of exporters of Common High Priority Items should include:
        • model risk management practices,
        • customer due diligence (‘know your customer’ (KYC)),
        • product life-cycle monitoring and tracking;
        • reporting from the compliance team to the management team;
        • reporting from commercial counterparts;
        • record-keeping procedures;
        • internal control systems;
        • involvement of senior management;
        • appointment of a compliance officer at management level; and
        • employee screening and training.
      • ‘No re-export to Russia’ clause. On December 18, 2024, the European Commission confirmed that a general clause prohibiting the re-exportation of prohibited goods to Russia can be sufficient if the other requirements set out in Article 12g of EU Regulation 833/2014 (notably the existence of adequate remedies) are satisfied. Furthermore, the FAQ stated that a unilateral communication to the counterparty prohibiting re-exportation to Russia is sufficient if the EU company concerned faces persistent difficulties in inserting the ‘no re-export to Russia’ clause in a contract.
    • Syria: On February 24, 2025 the European Union suspended the energy (including oil, gas and electricity) and transport sanctions imposed against Syria, and the asset-freeze measures imposed on five Syrian commercial banks and the Syrian Central Bank. This means that it is no longer prohibited to engage in transactions within these sectors, or with those Syrian banks. The European Commission explained that the Council “will also continue to closely monitor the situation in [Syria] to ensure that such suspensions remain appropriate.” These measures follow a similar action introduced by the US on January 6, 2025. The UK government has also announced its willingness to lift a number of UK sanctions against Syria on February 13, 2025.

    United Kingdom

    • New asset-freeze restrictions. On February 24, 2024, the United Kingdom imposed its “largest sanctions package since the early days of [Russia’s] invasion [of Ukraine].” In total, the United Kingdom sanctioned 107 new targets, covering producers and suppliers for Russia’s military, individuals and entities helping Russia to funnel foreign advanced technology to Russia, and North Korean officials complicit in helping Russia’s war efforts. For the first time ever, the United Kingdom sanctioned a foreign financial institution assisting Russia in accessing the international financial system.
    • New powers of OFSI: A of November 14, 2024, the UK Office of Financial Sanctions Implementation (OFSI) has the power to impose civil monetary penalties for breaching the prohibitions on investing in land in non-controlled Ukrainian territory or in Russia.
    • Reporting obligations: As of May 14, 2025, high value dealers, art market participants, insolvency practitioners and letting agencies will be required to report to OFSI their dealings with sanctioned persons and any suspicions relating to breaches of UK sanctions. This measure builds on the reporting requirements that cover UK regulated entities, such as banks or investment firms.
    • Licenses for intra-group services. Currently, the provision of restricted business services to group entities established in Russia is subject to a license from the UK Export Control Joint Unit (ECJU). As of October 31, 2024, any such activity is no longer considered by the ECJU as “likely to be consisted with” UK sanctions aims. This means that anyone wishing to obtain a license is now required to “explicitly demonstrate how such activity aligns with” UK sanctions, which adds additional complexity to the licensing process and widens the ECJU’s powers to refuse granting of any such licenses.
    • New guidance: On January 7, 2025, for the first time ever, OTSI issued guidance on UK trade sanctions. Specifically:
      • Trading under Russia sanctions. OTSI provided a user-friendly summary of trade sanctions against Russia, including explanations relating to: sanctions applicability, definitions and commodity codes, trading via third countries, professional and business services to persons connected with Russia, exceptions to trade sanctions and licenses to carry out prohibited activities, trade sanctions licensing, export control licensing, import control licensing, tariffs on Russian goods (including rules of origin), and shipping sanctions.
      • Circumvention: OTSI also issued guidance aimed at helping UK exporters reduce the risk of being targeted by companies seeking to evade sanctions. OTSI reiterated that UK businesses must fully determine the extent of their specific sanctions risk exposure and develop an appropriate set of safeguards and controls tailored to their business operations. This guidance was updated on February 25, 2025.
      • ‘No Russia’ clause: OTSI confirmed that while the UK Russia sanctions do not require the inclusion of a ‘no Russia’ clause in commercial agreements, the existence of such a clause should be considered best practice and may constitute a deterrent to non-UK persons seeking to redirect restricted goods to Russia.
    • Lite: A new system for applying for export licenses. The ECJU has rolled out a new system, Lite, for applying for standard individual export licenses (SIEL). However, applications for licenses relating to exports of restricted goods to sanctioned jurisdictions, such as Russia, should be still completed on the previous platform, SPIRE.

    Explore Further Insights

    Your Essential Guide to Recent US Policy and Law Developments

    Stay ahead of US law and policy changes, executive orders, and strategic shifts under the current administration with our US Policy Watch dedicated resource centre:

    • The latest insights and analyses on executive orders impacting employers, government contractors, privately held corporations, healthcare organizations, businesses engaging in global trade, and more;
    • Frequently asked questions about and checklists for responding to the president’s executive orders;
    • Webinar recordings examining the president’s executive orders, regulatory approach, and immigration agenda; and
    • Recent commentary from McDermott’s industry leaders on key issues.

    Conference on ‘Dealing with Sanctions and Anti-Corruption Compliance Issues After an Internal Audit’

    On January 23, 2025, McDermott Will & Emery, along with the French Compliance Society and the Association of Certified Sanctions Specialists (ACSS), organized a conference on ‘Dealing with Sanctions and Anti-Corruption Compliance Issues After an Internal Audit.’ Our expert panel of speakers provided insights into how authorities in France, the US and the UK address breaches and the strategies available for negotiation, giving participants a deeper understanding of compliance and enforcement nuances across these key regions.

    Speakers:

    • Edouard Shailend Leeleea, Group Compliance Officer at MBDA and President of the French Compliance Society
    • Arnaud Douville, General Counsel & Chief of Compliance at ERAMET
    • Raminta Dereskeviciute, Partner (London)
    • Nicolette Kost de Sèvres, Partner (Paris/Washington DC)
    • Sabine Naugès, Partner (Paris)

    Recent sanctions-related posts on our Regulatory and International Trade Blog:

    Authors
    More insights

  • Appeal against property tax assessment? Better late than never

    Appeal against property tax assessment? Better late than never

    ARTICLE

    Appeal against property tax assessment? Better late than never

    February 28, 2025

    Read time: 2 min

    Key takeaways
    Overview

    Andreas Klaus and Jonathan Storz with an article on “Legal remedy against property tax assessment? Better late than never”, published on Beck-Aktuell.

    In depth
    Authors

    Andreas Klaus, LL.M.

    Associate

    Munich

    Jonathan Storz

    Counsel

    Munich

    More insights

  • Recent Developments in Tax Law – New Developments in Conversion Tax Law

    Recent Developments in Tax Law – New Developments in Conversion Tax Law

    ARTICLE

    Recent Developments in Tax Law – New Developments in Conversion Tax Law

    2025

    Read time: 2 min

    Key takeaways
    Overview

    Dr. Gero Burwitz and Jonathan Storz with the article “Recent Developments in Tax Law News on Reorganization Tax Law”, published in Neue Zeitschrift für Gesellschaftsrecht (NZG).

    In depth
    Authors

    Dr. Gero Burwitz

    Partner

    Munich

    Jonathan Storz

    Counsel

    Munich

    More insights

  • German Battery Storage on a Rise – Recent developments and current legislative change

    German Battery Storage on a Rise – Recent developments and current legislative change

    ARTICLE

    German Battery Storage on a Rise – Recent developments and current legislative change

    February 27, 2025

    Read time: 9 min

    Key takeaways

    High and further increasing volatility of power prices due to the expansion of renewables on the one hand and significantly decreasing prices for battery cells in recent years on the other hand have led to a highly attractive market environment for battery storage (BESS) projects in Germany. The German legal framework for BESS projects is currently also in a process of changes: The German parliament adopted a comprehensive energy reform package on 31 January 2025, which includes relevant changes for BESS projects with the aim to further support the growth of storage capacities in Germany. Further current developments arise from the recent positioning of the German Federal Network Agency (Bundesnetzagentur – “BNetzA”) on specific legal matters such as grid connections or construction cost subsidies (Baukostenzuschüssen).

    In the following, we provide an overview of the recent developments of the legal framework of BESS projects and outline which obstacles to BESS projects still require further efforts by the new German government.

    1. Legislative Changes by the Energy Reform Package 2025

    On January 31 2025, the German Parliament adopted a comprehensive energy reform package which includes, inter alia, the following changes for BESS projects which are expected to enter into force in March 2025:

    Flexible grid connection agreements

    The reform package introduces the possibility of grid operators to offer flexible grid connection agreements – FCAs – (flexible Netzanschlussvereinbarungen) to their customers, which in particular allow the use of so-called “overbuilding” (Überbauung) and “cable pooling”. The new regulations are aimed at enabling a controlled, grid-supportive use of energy, especially at times of peak loads or oversupply, and reflect what has already partly been implemented in practice by grid operators at certain voltage levels. Plant operators can now choose a grid connection point that is already used by other plants of different types, including BESS (cable pooling). This may result in the installed capacity of a renewable energy plant and BESS project together exceeding the available grid connection capacity (overbuilding). In such cases, a flexible grid connection agreement between the grid operator on the one hand and the connected users on the other hand is required to control the feed-in in a controlled manner.

    Marketing options under the EEG for co-located BESS

    BESS can provide for an economically viable business model if co-located with onshore wind and solar PV plants whose generated electricity is in turn subsidized under the EEG. For this operational model, the energy reform package includes relevant changes to Section 19 EEG with the aim to further optimize the flexible usage options of BESS project. In the future, BESS operators will be able to choose between the following three options:

    • Exclusivity option (Ausschließlichkeitsoption – Section 19 (3a) EEG-new): Storage and feed-in exclusively of renewable electricity (green electricity).
    • Differentiation option (Abgrenzungsoption – Section 19 (3b) EEG-new): This option allows for a mixed use of the BESS, i.e. for storage of both grey and green electricity, and the different electricity quantities are treated differently in order to calculate the exact quantity of renewable electricity eligible for renewables remuneration.
    • Lump-sum option (Pauschaloption – Section 19 (3c) EEG-new): This option allows for a lump-sum renewables remuneration without exact measurement of the respective electricity quantities and is designed for smaller plants to allow the use of BESS without a too high administrative burden. This option is only available to operators of smaller solar plants with a maximum installed capacity of 30 kW.

    The actual implementation of the two latter options still depends on further specifications by the Federal Network Agency (“BNetzA”), which is obliged to define the specific requirements for the quantities of electricity eligible for EEG remuneration at the latest by 30 June 2026.

    2. Further Developments Due to the Positioning of the BNetzA

    (Failed) attempt to establish a new grid connection procedure

    The attractive market environment for BESS projects has recently led to a sharp increase in grid connection requests which currently sum up to more than 200 GW only for BESS above 1 MW. Given the increasing shortage of grid connection capacities, BNetzA has published a consultation paper end of last year in which the agency presented its favored so-called “repartitioning model” (Repartierungsmodell) for discussion. According to this model, available grid connection capacities shall be allocated equally on specific dates, with a pro rata (proportional to the amount of requested capacity) or per capita (equal shares) distribution among all applicants. However, after evaluating the statements of market participants in February 2025, the BNetzA recently withdrew from further developing a position paper, as the repartitioning model it proposed could not gain consensus in the market.

    As a result, it remains the responsibility of the individual, more than 850 German grid operators, to develop and apply a procedure for allocating grid connection capacities. There is thus no uniform approach of grid operators for the allocation of grid capacities, even though the “first come, first served model” is still the most frequently used procedure by grid operators.

    Position paper on construction cost subsidies

    Construction cost subsidies are economically relevant for the development of BESS projects, as they can make up to 15% of the investment costs. The handling and permissibility of construction cost subsidies has been controversial in practice to date and is the subject of ongoing legal proceedings at the Federal Court of Justice (BGH) in Germany.

    Notwithstanding, BNetzA has published a new position paper on construction cost subsidies for BESS end of last year, in which it upholds its existing position that grid operators are basically entitled to charge construction cost subsidies for grid connections of BESS projects above the low voltage. BNetzA has made further adjustments in relation to the calculation based on the existing capacity price model (Leistungspreismodell) and has introduced the concept of a differentiated discount scheme: while TSOs have the option of granting discounts of up to 80% on construction cost subsidies, particularly in northern Germany (control areas of TenneT and 50 Hertz), this does not apply to DSOs or to TSOs in southern Germany. This means that significant local cost differences may arise.

    3. Remaining Challenges for BESS Projects and Need for Further Legal Adjustments

    Despite the previous legislative changes, further amendments to the legal framework are necessary to make the development and expansion of BESS as efficient as possible. These include the following areas for improvement.

    Planning: BESS as privileged projects

    BESS projects are typically built in so-called outer areas (Außenbereich) and are therefore only permissible without a prior zoning plan procedure if they qualify as a so-called “privileged project” pursuant to Section 35 (1) nos. 1 to 9 BauGB. As BESS projects are not expressly listed in Section 35 (1) BauGB, and as most federal states have not yet defined uniform administrative practices in assessing whether BESS can still be regarded as privileged projects, BESS developers currently need to assess and discuss with the local authorities on a case-by-case basis whether a project is permissible in the outer areas, or whether they may need to undergone a significantly more burdensome and time-intensive zoning plan procedure first.

    This lack of clarity with regard to planning procedures for BESS, while still understandable in times where the number of BESS projects was much smaller, is considered as increasingly unsatisfactory by BESS developers in times where a large upscaling of BESS is actually needed. The German legislator should therefore consider to adjust existing planning laws to appropriately reflect the importance of BESS projects as flexibility options.

    Permitting: Further simplifications

    Based on the applicable state building ordinance of the respective German federal state in which the BESS project is located, BESS projects currently require a building permit which is generally granted in a simplified building permit procedure. The first federal states (e.g. Bavaria) have recently introduced further simplifications to permitting law, according to which BESS projects may no longer require a building permit at all under certain circumstances (e.g. if the BESS project is to be classified as a privileged project according to Section 35 (1) no. 3 BauGB). It will be necessary to continue monitoring whether all federal states will now introduce more extensive and uniform simplifications for the permitting of BESS projects and whether and to which extent such developments will actually contribute to a further acceleration of the project development process.

    Grid connection: capacity allocation and construction cost subsidies

    A continued point of focus will be the future handling of construction cost subsidies and grid allocation procedures. While construction cost subsidies, correctly applied, may be a sensible tool to allocate BESS projects to the right regions and to limit the number of grid connection requests to projects that are actually pursued and to avoid duplicate connection requests for the same projects, the question remains how the existing procedures for grid connections of BESS projects can be shaped in a more efficient and speedy way. Whereas streamlining of grid connection procedures may partly be addressed by new regulations and administrative action by the BNetzA (e.g. in relation to digitalization and harmonization of plant certification procedures), the grid operators and the plant operators together may need to find a way to effectively apply flexible capacity allocation and it may be the better solution to avoid further regulation and administrative burdens.

    Do You Need Further Information or Legal Assistance?

    We will be happy to assist you with legal advice on all aspects of the current developments for BESS projects in Germany or on any questions in relation to the German legal framework for BESS projects.

    Please do not hesitate to get in touch with us!

    In depth
    Authors
    More insights

  • Judicial “upward adjustment” violates collective bargaining autonomy

    Judicial “upward adjustment” violates collective bargaining autonomy

    ARTICLE

    Judicial “upward adjustment” violates collective bargaining autonomy

    February 26, 2025

    Read time: 2 min

    Key takeaways
    Overview

    The HR News blog provides regular updates on recent developments in German employment law (in German). The latest blog post provides insights on “EU AI Regulation: When AI competence becomes mandatory“.

    Visit the blog and/or register now for regular HR NEWS updates (in German).

    In depth
    Authors
    More insights

  • Federal Court Blocks Trump’s DEI-Related Executive Orders Nationwide

    Federal Court Blocks Trump’s DEI-Related Executive Orders Nationwide

    CLIENT ALERT / US POLICY

    Federal Court Blocks Trump’s DEI-Related Executive Orders Nationwide

    February 25, 2025

    Read time: 3 min

    Key takeaways
    Overview

    Shortly after taking office, President Donald Trump issued two executive orders (EOs) targeting diversity, equity, and inclusion (DEI) programs: EO 14151, “Ending Radical And Wasteful Government DEI Programs and Preferencing,” and EO 14173, “Ending Illegal Discrimination And Restoring Merit-Based Opportunity” (collectively, the DEI-related EOs).

    On February 21, 2025, following a lawsuit filed by the National Association of Diversity Officers in Higher Education and the American Association of University Professors (collectively, the plaintiffs), the US District Court for the District of Maryland granted a motion for preliminary injunction based on First and Fifth Amendment challenges to the DEI-related EOs. The court’s order prevents certain aspects of the EOs from taking effect nationwide until a final determination is made on the plaintiffs’ constitutional challenge.

    In depth

    Legal Overview

    The plaintiffs challenged the following three specific provisions in the DEI-related EOs as being unconstitutional:

    1. Termination Provision: A provision that directed federal agencies to terminate “equity-related” grants or contracts within 60 days.
    2. Certification Provision: A provision that required federal agencies to include a term in contracts and grants requiring federal contractors and grantees to certify that they do not operate any programs promoting DEI that violate federal anti-discrimination laws as a condition of receiving funding.
    3. Enforcement Threat Provision: A provision that directed the attorney general to take measures to deter DEI programs and identify potential civil compliance investigations.

    The plaintiffs argued that these provisions collectively violate the First and Fifth Amendments because they are designed to chill viewpoint speech. They also asserted that the provisions are unconstitutionally vague in informing federal contractors that may be exposed to liability under the False Claims Act what their obligations are and how to comply with them.

    The court agreed with the plaintiffs, concluding that:

    1. The Certification and Enforcement Threat Provisions likely violate the First Amendment by chilling speech and imposing viewpoint-based restrictions; and
    2. The Termination and Enforcement Threat Provisions are likely unconstitutionally vague, failing to provide clear guidance and inviting arbitrary enforcement.

    What Companies Should Do Next

    While the nationwide injunction pauses some of the more controversial provisions included in the DEI-related EOs, it is only a preliminary finding, and the Trump administration may take steps to challenge it. Companies should use this time to work with legal counsel to proactively audit their DEI policies to ensure compliance with existing laws while maintaining alignment with company values.

    Joseph Anderson, a law clerk in New York office, also contributed to this client alert.

    Authors

    Tara L. Ward

    Partner

    Washington, DC

    Joseph Anderson

    Associate

    New York – One Vanderbilt Avenue

    More insights

  • FDA Reveals AI Development Cheat Sheet in Highly Anticipated Draft Guidances

    FDA Reveals AI Development Cheat Sheet in Highly Anticipated Draft Guidances

    ARTICLE / CLIENT ALERT

    FDA Reveals AI Development Cheat Sheet in Highly Anticipated Draft Guidances

    February 24, 2025

    Read time: 11 min

    Key takeaways
    Overview

    Early in the new year, the US Food and Drug Administration (FDA) released two anticipated draft guidance documents focused on artificial intelligence (AI): Artificial Intelligence-Enabled Device Software Functions: Lifecycle Management and Marketing Submission Recommendations (draft AI-enabled device guidance) and Considerations for the Use of Artificial Intelligence to Support Regulatory Decision-Making for Drug and Biological Products (draft AI drug guidance).

    In the draft AI-enabled device guidance, FDA describes the data and information it expects device sponsors to include in their marketing submissions for AI-enabled devices. FDA also offers recommendations for lifecycle management of AI models in the guidance and includes example submission materials to illustrate how device sponsors might operationalize the draft guidance. Drawing on risk-based frameworks from the device context, the draft AI drug guidance provides a seven-step framework for developing and executing an assessment of an AI model’s performance to determine whether a model used to support decisions about a drug’s efficacy, safety, or quality is effective and fit for the intended purpose.

    The draft guidance documents emphasize AI transparency, life cycle management, and early engagement with FDA when using AI. Stakeholders intending to use AI in ways subject to FDA oversight should ensure they adequately document how they develop, validate, and monitor the performance of AI models and outputs. The guidance documents demonstrate that FDA is focused on the quality of data used throughout an AI model’s life cycle, whether a given model is fit for the intended purpose and user, and how a model will be monitored over time.

    Comments on the draft guidance documents are due by April 7, 2025. Differences between these draft documents and the finalized guidance may offer insight into whether the FDA under the new Trump administration will approach AI differently than its predecessor.

    In depth

    Draft AI-Enabled Device Guidance

    The draft AI-enabled device guidance is the latest in a series of FDA resources taking a total product life cycle approach to developing and monitoring AI-enabled devices. The draft AI-enabled device guidance offers recommendations for the information and data that sponsors should include in marketing submissions for devices with AI-enabled software functions and provides general strategies for the design and development of AI-enabled devices.

    While FDA is clear that its other guidance documents on devices remain applicable to AI-enabled devices, the draft AI-enabled device guidance offers more details on the kinds of information that sponsors of AI-enabled devices should include about their products in marketing submissions.

    Among other things, the draft AI-enabled device guidance recommends that marketing submissions for AI-enabled devices address the following:

    • Device Description. The device description should include information about the model’s inputs and outputs and how AI is used to achieve the device’s intended use. The intended users and use environment, clinical workflow, and degree of automation compared to the current standard of care should also be described. The device description should explain whether the device requires regular calibration or includes configurable elements.
    • User Interface and Labeling. Marketing submissions should allow FDA to understand what device elements users interact with and what information is communicated to users of the device throughout the device’s workflow. This includes any alerts or other communications to the user about the risks or limitations of the AI-enabled device, information about the AI model and its performance, and descriptions of the interface and operational sequence of the device.

    The recommendations suggest that one of FDA’s major concerns about AI-enabled devices is that users will not understand the limitations of the device and its AI functionality. FDA appears to be emphasizing that transparency within its labeling framework is part of the solution. Per the guidance, all users should be provided with information about the device’s AI models, its proper use, and its limitations in a format and at a reading level appropriate to the given user. FDA encourages sponsors to use model cards to concisely communicate key elements of an AI-enabled device to users and includes an example of a completed model card in the guidance. We underscore that the model card included in the guidance is an example and any model card developed by a manufacturer should be customized to the relevant device and context for use.

    • Risk Assessment. The risk management file included in a marketing submission for an AI-enabled device should include a risk assessment of the device that takes into consideration the unique risks posed by AI. FDA urges designers to consider user tasks and knowledge tasks that occur at all stages of the device use – from installation to interpretation of the results – as part of the risk assessment.
    • Data Management. In the draft AI-enabled device guidance, FDA repeatedly emphasizes the importance of data quality to developing and validating AI-enabled devices. Reflecting this, marketing submissions for AI-enabled devices should detail the sponsor’s data management practices. The marketing submission should explain how data is cleaned, processed, annotated, stored, used, and controlled. The submission should also describe how data has been or will be collected and should characterize the data used to develop and validate the AI-enabled device.

    FDA notes in the draft AI-enabled device guidance that data quality is a key performance driver for AI models and can help mitigate and reduce bias. To this end, FDA advises sponsors to provide information on the independence of test data from data used to develop an AI model, reference standards used in device development, and the representativeness of data.

    • Model Description and Development. Marketing submissions should include information about the characteristics of each AI model used in the device – distinct from descriptions of the device as a whole. Descriptions of the models should be included in the software description section of the submission and should address the inputs and outputs, model architecture, model parameters, and how the model was trained. When a device involves multiple models, FDA encourages use of charts or other diagrams to help map the relationship between the inputs, operation, and outputs of each model.

    FDA repeatedly notes its concern that it perceives opacity in many AI models and that this can be a source of risk in medical devices. In line with the emphasis on transparency throughout the guidance, FDA expects sufficient information on AI models to permit FDA to understand the functionality of an AI-enabled device and to identify potential limitations, sources of bias, and other considerations for appropriate labeling.

    • Validation. Validation information should provide objective evidence of an AI model’s performance with respect to the intended use. Validation should be performed using a dataset independent from that used to train or develop the model. FDA notes that validation will look different depending on the device and the underlying models, but submissions should provide information about the studies performed to validate the device’s performance.
    • Device Performance Monitoring. Recognizing that AI-enabled devices can experience changes in performance over time, FDA urges sponsors of AI-enabled devices to proactively monitor and address changes in device performance. Sponsors that choose to employ performance monitoring to control risk and provide reasonable assurance of device safety and effectiveness should include information about such performance monitoring plans in their market submissions.
    • Cybersecurity. FDA urges sponsors to address the cybersecurity risks of AI in their submissions. In addition to pointing sponsors to other FDA guidance on cybersecurity, the FDA flags AI risks that can be exacerbated by cybersecurity threats, including data poisoning, data leakage, overfitting, model bias, and performance drift. Marketing submissions should address AI-specific cybersecurity concerns in the cybersecurity/interoperability section.

    The draft AI-enabled device guidance also includes recommendations on the information that public submission summaries should cover. FDA again encourages sponsors to consider using a model card to organize and present key information about an AI-enabled device. Finally, appendices to the guidance provider sponsors with further recommendations on transparency, performance validation, and device usability that can be used to inform a total product life cycle approach to device design. The appendices also include helpful examples of a model card and 510(k) summary for an AI-enabled device.

    Draft AI Drug Guidance

    FDA also issued its first guidance document specifically addressing the use of AI in drug and biologic product development. This guidance was developed collaboratively by FDA’s human and animal medical product centers, the Office of Inspections and Investigations, the Oncology Center of Excellence, and the Office of Combination Products. The draft guidance reflects a years-long effort by FDA to develop its approach to AI in this area. FDA has previously issued discussion papers, sponsored workshops, and solicited public comments related to the use of AI in drug development.

    The draft AI drug guidance describes a risk-based framework for sponsors to assess and establish the credibility of an AI model for a specific context of use when the model will be used to produce information to support regulatory decision-making regarding safety, effectiveness, or quality for drugs or biological products. Context of use refers to how an AI model is used to address a certain question of interest. The draft AI drug guidance does not apply to AI uses in drug discovery or operations not impacting patient safety, drug quality, or the reliability of results from clinical or nonclinical studies. Instead, the draft guidance’s scope includes predicting patient outcomes, integrating and processing large datasets to develop clinical trial endpoints, and helping select manufacturing conditions.

    FDA highlights three challenges unique to AI that inform the draft AI drug guidance:

    • The reliability of outputs produced by AI models depends on the quality, size, and representativeness of datasets used to train the model.
    • The complexity and opacity of many AI models makes it difficult to determine how models arrive at a given conclusion and necessitates transparency in the development of a model.
    • The performance of many AI models may shift or change over time or across deployment environments.

    In light of these challenges, FDA considers establishing an AI model’s credibility for a given use to be essential. Doing so requires thoughtful consideration in the development, training, and deployment of an AI model. Throughout the model’s life cycle, the model’s risks, limitations, and performance should be monitored and documented.

    The seven-step framework described in the draft drug AI guidance is similar to assessment frameworks developed for medical devices. The first two steps of the framework described in the draft AI drug guidance ask the AI user to first define the question, decision, or concern to be addressed by the AI model and to consider the context of use (i.e., the specific role and scope of the AI model in answering the question of interest).

    The next steps are to assess the risks of the contemplated AI model and to develop a plan to assess the model’s credibility in the context of use. The guidance includes detailed recommendations on the contents of a credibility assessment plan, although FDA acknowledges that whether a plan must be submitted to FDA will depend on how the sponsor engages with FDA, the AI model, and context of use. A credibility assessment plan should include a description of the model, its training, and the sponsor’s rationale for selecting the specific modeling approach. The plan should then detail how the model will be evaluated and include information on how the data used to evaluate the model was collected, the metrics used to measure the model’s performance, limitations of the model, and the sponsor’s rationale for this assessment approach.

    Finally, a sponsor should execute the plan, document the results from the credibility assessment, and determine the adequacy of the AI model for the context of use. If the results do not support the credibility of the model for the context of use, FDA suggests several options for how a sponsor might respond. For example, the sponsor could downgrade the model’s influence in answering the question of interest by incorporating additional types of evidence. The sponsor might also increase the rigor of the assessment and further train the model, establish additional protocols to mitigate model risk, or alter the modeling approach. Beyond the seven-step framework, the draft AI drug guidance emphasizes the importance of continued monitoring of AI model performance to address model drift. The draft AI drug guidance lists options for interfacing with FDA on AI model development and encourages early and transparent engagement on these issues by sponsors and other interested parties.

    *  *  *

    For more information on these draft guidance documents or other recent FDA guidance on AI, contact the authors of this article or any other member of McDermott’s Food, Drug & Medical Device Regulatory Group.

    Authors

    James R. Ravitz

    Partner

    Washington, DC

    Paul S. Gadiock

    Partner

    San Francisco

    Jennifer S. Geetter

    Partner

    Washington, DC

    Marissa Hill Daley

    Law Clerk

    Washington, DC

    Nathan Gray

    Associate

    Washington, DC

    More insights

  • How PPM Health Plans Can Solve the MEWA Problem

    How PPM Health Plans Can Solve the MEWA Problem

    ARTICLE / CLIENT ALERT

    How PPM Health Plans Can Solve the MEWA Problem

    February 24, 2025

    Read time: 4 min

    Key takeaways
    Overview

    While a physician practice management (PPM) structure allows for compliance with corporate practice of medicine laws and ease of administration, it often creates inadvertent health plan issues that should be navigated carefully to avoid compliance issues and/or difficulties with selling PPM entities.

    In depth

    MEWA Problem

    The PPM structure helpfully allows physicians to focus on the clinical practice of medicine through a physician practice professional corporation (PC), while outsourcing the business of the practice of medicine to a management services organization (MSO, which, together with the PC, is referred to as the PPM). Ideally, employees of the MSO and employees of each PC associated with the PPM structure could be combined and covered under a single group health plan to allow for experience rating of a larger group of employees, which leads to cost savings for the PPM structure and all employees, and simplifies the offering of healthcare coverage administration.

    Because the MSO and the PC under the PPM structure typically do not have adequate common ownership – purposefully so to ensure the PPM structure complies with the corporate practice of medicine rules – allowing the PC and MSO entities to participate in the same health plan can create health plan compliance concerns, such as a multiple employer welfare arrangement (MEWA). It is preferable to avoid creation of a MEWA, as MEWA requirements can be burdensome and prohibitive, including exposure to state laws (some of which outlaw self-funded MEWAs) and extensive reporting requirements to certain states and the US Department of Labor. As a result, having a MEWA can result in state and/or federal penalties and the structure presents significant complications when it comes to selling the PPM to a third party.

    MEWA Alternatives

    All, however, is not lost. Rather than separately purchasing commercially available group health insurance (e.g., in the small group market, which is expensive and lacking in transparency), MSOs and PCs have several other options to provide group health plan coverage and avoid or accommodate being a MEWA. These include the following:

    • The MSO and PCs establish “mirror plans,” where each entity maintains a self-funded group health plan but stop-loss insurance may be pooled among entities. Alternatively, the MSO and PCs may use a group captive medical stop-loss structure to manage risk associated with stop-loss insurance for self-funded plans.
    • The MSO and PCs establish separate “level-funded” plans, where the MSO and PCs establish and maintain their own self-funded group health plans.
    • The MSO and PCs purchase fully insured group health coverage that is underwritten as a single, large group through a professional employer organization (PEO). While this usually in fact creates a MEWA, MEWA compliance is the responsibility of the PEO provider not the PPM structure.

    For more information regarding MEWAs and potential alternative options for PPM entities to provide group health plan coverage, please refer to our Special Report, Examining Group Health Coverage Alternatives for Small Employers. If you have any additional questions about these issues, please contact your regular McDermott lawyer or one of the authors listed below.

    Authors

    Sarah G. Raaii

    Partner

    Chicago

    Erin Turley

    Partner

    Dallas

    Allison Wilkerson

    Partner

    Dallas

    More insights